Cardiovascular Drugs and Therapy

, Volume 24, Issue 2, pp 175-180

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial

  • Michael G. HennericiAffiliated withDepartment of Neurology, University of HeidelbergUniversity of Heidelberg, Universitätsmedizin Mannheim UMM Email author 
  • , Michiel L. BotsAffiliated withJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht
  • , Ian FordAffiliated withRobertson Centre for Biostatistics
  • , Stéphane LaurentAffiliated withDepartment of Pharmacology and INSERM U970, Hôpital Européen Georges Pompidou
  • , Pierre Jean TouboulAffiliated withDepartment of Neurology and Stroke Center, Hôpital Bichat



PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients.

Methods and results

The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006.


The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs.

Key words

Antiatherosclerotic activity Antiplatelet agent Atherosclerosis Carotid intima-media thickness Ischemic stroke Carotid plaque Clinical trial